• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Menu
    • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy

    Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

    Explore Muscle

    • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious muscle diseases with unmet medical needs.

    Explore our Science

    • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories

    We honor the experience of individuals and families living with and facing the challenges of serious muscle disease.

    Read their Stories

    • Company
    • Leadership Team
    • Careers
    • Contact Us

    Our vision is to improve the lives of patients and families suffering from serious muscle diseases by building the world’s leading muscle-focused company.

    Learn More

    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomeScience & PipelineSevasemten

Sevasemten

Targeting contraction-induced muscle injury

We developed sevasemten with the aim to address the root cause of muscle breakdown in muscular dystrophies, contraction-induced muscle damage. All muscles contract during daily activities.

In muscular dystrophies, the muscle lacks protective components including the fully functional protein dystrophin. When muscle fibers are not protected and unstable, contraction-induced injury starts a repetitive cycle that ultimately leads to fat and scar and fibrosis in the muscle, and loss of function

Contraction-Induced Muscle Damage in Muscular Dystrophies

Healthy Muscle

Dystrophic Muscle

About Sevasemten

Investigational therapy for Becker and Duchenne

Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect unstable muscle against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne.

See sevasemten development progress

Designed to preserve and protect fast muscle fibers

By minimizing the progressive muscle damage that leads to functional impairment, sevasemten has the potential to benefit a broad range of patients suffering from debilitating skeletal muscle disorders either as a single agent therapy or in combination with available therapies and those in development.

View sevasemten presentations

Clinical trials of sevasemten in Becker and Duchenne are ongoing

Sevasemten is currently in late-stage clinical trials with investigational study sites across the globe.

Learn more about sevasemten clinical trials

Watch sevasemten in real-time

Dr. Alan Russell, Edgewise Co-founder and Chief Scientific Officer, explains how sevasemten protects dystrophic muscle from damage in an animal model of Duchenne.

Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.

Footer

Edgewise Therapeutics
  • Disease Areas
  • Science & Pipeline
  • Patients & Families
  • Company
  • Investors & News

Deep knowledge of integrated 
muscle physiology

Learn more about how our science is driving a new understanding of muscle and its potential to transform human health.

Explore our Science

2025 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Disease Areas
    • Muscular Dystrophy
    • Hypertrophic Cardiomyopathy
  • Science & Pipeline
    • Pipeline
    • Sevasemten
    • EDG-7500
    • Clinical Trials
    • Posters & Presentations
  • Patients & Families
    • Support for Becker
    • Support for Duchenne
    • Support for HCM
    • Patient Stories
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts